{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:29:33Z","timestamp":1758400173380},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1208\/s12248-018-0274-x","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T16:25:47Z","timestamp":1541521547000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Approaches to Resolve False Reporting in Neutralizing Antibody Assays Caused by Reagent Leaching from Affinity Capture Elution Solid Phase"],"prefix":"10.1208","volume":"21","author":[{"given":"Yuhong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kamerud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Donley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Caiazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuenlei","family":"Parng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gorovits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"issue":"6","key":"274_CR1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2174\/138920108786786411","volume":"9","author":"A Beck","year":"2008","unstructured":"Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol. 2008;9(6):482\u2013501.","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"274_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1158\/1541-7786.MCR-09-0314","volume":"8","author":"J Beck","year":"2010","unstructured":"Beck J, Urnovitz HB, Mitchell WM, Schutz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res : MCR. 2010;8(3):335\u201342.","journal-title":"Mol Cancer Res : MCR"},{"issue":"9","key":"274_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","volume":"317","author":"PJ Carter","year":"2011","unstructured":"Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011;317(9):1261\u20139.","journal-title":"Exp Cell Res"},{"key":"274_CR4","volume-title":"Immunogenicity assessment for therapeutic protein products","author":"FDA","year":"2014","unstructured":"FDA. Guidance for industry. In: Immunogenicity assessment for therapeutic protein products; 2014."},{"issue":"2","key":"274_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.biologicals.2011.01.006","volume":"39","author":"IC Buttel","year":"2011","unstructured":"Buttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals. 2011;39(2):100\u20139.","journal-title":"Biologicals"},{"issue":"1\u20132","key":"274_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2008.01.001","volume":"333","author":"E Koren","year":"2008","unstructured":"Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1\u20132):1\u20139.","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"274_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1\u20132):1\u201316.","journal-title":"J Immunol Methods"},{"issue":"5","key":"274_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"key":"274_CR9","doi-asserted-by":"crossref","unstructured":"Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007;25(5):555\u2013561.","DOI":"10.1038\/nbt1303"},{"key":"274_CR10","first-page":"15","volume":"112","author":"AS Rosenberg","year":"2003","unstructured":"Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol. 2003;112:15\u201321.","journal-title":"Dev Biol"},{"issue":"Suppl 2","key":"274_CR11","first-page":"II4","volume":"251","author":"H Schellekens","year":"2004","unstructured":"Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251(Suppl 2):II4\u20139.","journal-title":"J Neurol"},{"issue":"7","key":"274_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469\u201375.","journal-title":"N Engl J Med"},{"key":"274_CR13","doi-asserted-by":"crossref","unstructured":"Green D. Spontaneous inhibitors to coagulation factors. Clin Lab Haematol 2000;22 Suppl 1:21\u201325; discussion 30-2.","DOI":"10.1046\/j.1365-2257.2000.00001.x"},{"issue":"12","key":"274_CR14","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","volume":"98","author":"J Li","year":"2001","unstructured":"Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241\u20138.","journal-title":"Blood"},{"key":"274_CR15","doi-asserted-by":"crossref","unstructured":"Hu J, Gupta S, Swanson SJ, Zhuang Y. A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum. J Immunol Methods 2009;345(1\u20132):70\u201379.","DOI":"10.1016\/j.jim.2009.04.005"},{"issue":"1\u20132","key":"274_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","volume":"327","author":"JS Bourdage","year":"2007","unstructured":"Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1\u20132):10\u20137.","journal-title":"J Immunol Methods"},{"issue":"3","key":"274_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.yrtph.2007.07.005","volume":"49","author":"HW Smith","year":"2007","unstructured":"Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol : RTP. 2007;49(3):230\u20137.","journal-title":"Regul Toxicol Pharmacol : RTP"},{"issue":"1\u20132","key":"274_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jim.2005.10.007","volume":"308","author":"JA Lofgren","year":"2006","unstructured":"Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods. 2006;308(1\u20132):101\u20138.","journal-title":"J Immunol Methods"},{"key":"274_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jim.2014.11.005","volume":"416","author":"W Xu","year":"2015","unstructured":"Xu W, Jiang H, Titsch C, Haulenbeek JR, Pillutla RC, Aubry AF, et al. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. J Immunol Methods. 2015;416:94\u2013104.","journal-title":"J Immunol Methods"},{"issue":"5","key":"274_CR20","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1021\/ac5001465","volume":"86","author":"H Jiang","year":"2014","unstructured":"Jiang H, Xu W, Titsch CA, Furlong MT, Dodge R, Voronin K, et al. Innovative use of LC-MS\/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development. Anal Chem. 2014;86(5):2673\u201380.","journal-title":"Anal Chem"},{"issue":"5","key":"274_CR21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jpba.2011.03.038","volume":"55","author":"S Gupta","year":"2011","unstructured":"Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55(5):878\u201388.","journal-title":"J Pharm Biomed Anal"},{"key":"274_CR22","unstructured":"EMA. Guideline on Immunogenicity assessment of 6 biotechnology-derived therapeutic proteins. 2015."},{"issue":"5","key":"274_CR23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/clinchem\/37.5.625","volume":"37","author":"EP Diamandis","year":"1991","unstructured":"Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem. 1991;37(5):625\u201336.","journal-title":"Clin Chem"},{"key":"274_CR24","doi-asserted-by":"crossref","unstructured":"Heitzmann H RF (1974) Use of the avidin-biotin complex for specific staining of biological membranes in electron microscopy. Proceedings of the National Academy of Sciences USA 71(9):3537\u201341.","DOI":"10.1073\/pnas.71.9.3537"},{"issue":"8","key":"274_CR25","doi-asserted-by":"publisher","first-page":"12531","DOI":"10.3390\/molecules190812531","volume":"19","author":"M Kohler","year":"2014","unstructured":"Kohler M, Karner A, Leitner M, Hytonen VP, Kulomaa M, Hinterdorfer P, et al. pH-dependent deformations of the energy landscape of avidin-like proteins investigated by single molecule force spectroscopy. Molecules. 2014;19(8):12531\u201346.","journal-title":"Molecules"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-018-0274-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T20:06:01Z","timestamp":1605384361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-018-0274-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1208\/s12248-018-0274-x","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"30 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"4"}}